Incidence, Risk Factors and Ophthalmic Clinical Characteristic of Ethambutol-induced Optic Neuropathy: 7-year Experience in Rajavithi Hospital, Thailand.
- Conditions
- Ethambutol, optic neuropathy, tuberculosis, risk factor, incidence, clinicalEthambutol optic neuropathy
- Registration Number
- TCTR20220207006
- Lead Sponsor
- Rajavithi Hospital
- Brief Summary
The incidence of EON in patients treated with Ethambutol was 0.5%. Age, hypertension, smoking, and duration of ethambutol prescription were risk factors for EON. Some intriguing ophthalmic studies showed loss of retinal nerve fibers, which was more noticeable in the ganglion cell layer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
1. The patients who received ethambutol for TB treatment at Rajavithi Hospital, Bangkok, Thailand from January 2012 to August 2019.
2. The patients who had decreased vision after ethambutol treatment and were diagnosed as ethambutol-induced optic neuropathy (EON) by experienced neuro-ophthalmologists were included as EON group.
3. The patients who received ethambutol during the study period without visual symptoms were included as Control group.
1. EON patients with other ophthalmic conditions resulting in significant visual obscuration such as retinal and macular diseases, cataract, diabetic retinopathy, glaucoma, or other optic neuropathies were excluded.
2. The patients who had incomplete or lost medical record.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence, risk factor, clinical n/a number and opd record
- Secondary Outcome Measures
Name Time Method ophthalmic investigation result n/a ophthalmic investigation machine